{"id":88115,"topic":"peptides","source":"搜狐网","title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","url_hash":"7f5a65c00cfa6aaca8f4a2e9c32847aec5725a84","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPS19INDA2aUdIckJJWmxqNmctZXc1SnZsbUZ5M2JpM1JicWZlaXo0dDVsTVlZR256aUtOdlZCWjhESjhjYWpWTTFOQkRPOHQxTjNMNGZLSHphUTRkbHMxN3RDMVlfM3R0SUNLTWhmS3NQdDdmbFdCRkRmN0hZblpQejB1MTZHenNF?oc=5\" target=\"_blank\">多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","content":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","image_url":"https://q3.itc.cn/q_70/images03/20260922/8c67a783d59142408e5e2ba1e8a0a09c.jpeg","lang":"zh","published_at":"2026-09-22T13:19:57+00:00","fetched_at":"2026-09-22T14:15:13+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}},"news_item":{"id":88115,"canonical_url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source_url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","source_name":"搜狐网","author":null,"published_at":"2026-09-22T13:19:57+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPS19INDA2aUdIckJJWmxqNmctZXc1SnZsbUZ5M2JpM1JicWZlaXo0dDVsTVlZR256aUtOdlZCWjhESjhjYWpWTTFOQkRPOHQxTjNMNGZLSHphUTRkbHMxN3RDMVlfM3R0SUNLTWhmS3NQdDdmbFdCRkRmN0hZblpQejB1MTZHenNF?oc=5\" target=\"_blank\">多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","full_text":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","excerpt":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 444 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","source":"搜狐网","date":"2026-09-22T13:19:57+00:00","content":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 444 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/88115","export_markdown":"/api/items/88115/export?format=markdown","export_json":"/api/items/88115/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"formats":{"full":{"id":88115,"title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","author":null,"published_at":"2026-09-22T13:19:57+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","full_text":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 444 characters.","diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}},"actions":{"read":"/item/88115","export_markdown":"/api/items/88115/export?format=markdown","export_json":"/api/items/88115/export?format=json","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"}},"digest":{"id":88115,"title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","source":"搜狐网","topic":"peptides","published_at":"2026-09-22T13:19:57+00:00","excerpt":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。 圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。 根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 444 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","subtitle":"搜狐网 · 2026-09-22","summary":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。 圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。…","badges":["quality:high"],"links":{"read":"/item/88115","original":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","diagnose":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334"},"quality_warning":null},"export":{"title":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单 - 搜狐网","url":"https://m.sohu.com/a/1079618192_222256?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334","summary":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","source":"搜狐网","date":"2026-09-22T13:19:57+00:00","content":"多肽原料药对美销售全面暂停 圣诺生物子公司遭FDA列入进口警示名单\n《科创板日报》9月22日讯（记者 史士云）今日，圣诺生物（688117.SH）发布公告称，其全资子公司成都圣诺生物制药有限公司（以下简称“圣诺制药”）被美国FDA列入第66-40号进口警示名单，意味着圣诺生物相关产品进入美国市场将遭遇直接阻碍。\n圣诺生物方面也在公告中称，在相关警示解除前， 圣诺制药将全面停止所有多肽原料药对美国市场的销售与发运。\n根据FDA的相关规定，被FDA列入进口警示的厂区在进行整改并得到FDA确认后，或通过FDA重新现场检查后才能解除其进口警示。\n数据显示，2025年全年，圣诺生物来自美国市场的销售收入为1.53亿元，占当期总营收20.19%。 而2026年上半年，公司对美销售收入已达1.67亿元，营收占比攀升至 32.83%，美国市场对于圣诺生物的重要程度不言而喻。\n受上述消息冲击，圣诺生物股价今日大跌18.61%，创下近一年来新低，收盘报19.99元/股，最新市值为44.05亿元。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//m.sohu.com/a/1079618192_222256%3Fscm%3D10001.325_13-325_13.0.0-0-0-0-0.5_1334","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 444 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 444 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":444,"summary_length":444,"usable_text_length":444,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":444,"summary_length":444}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}